{
  "data": [
    {
      "ingredient2": "Famciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205079,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205342,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205475,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205545,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205951,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206738,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206995,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207161,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207344,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Brimonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207576,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dicloxacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207693,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207763,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207899,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207946,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208190,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208292,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208518,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208713,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209009,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209308,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209388,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209727,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210024,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210215,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210712,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211115,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211415,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211627,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212014,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212055,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212352,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Bacitracin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212403,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212725,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213259,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213967,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214160,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214411,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214977,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216222,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216663,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Isoflurane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216769,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216842,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217457,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Alprostadil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217555,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217667,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Phenelzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217813,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217841,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218127,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218877,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219208,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Acetazolamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219603,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219704,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219930,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220275,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Chlorhexidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220953,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221170,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221568,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221671,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221964,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222144,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Amantadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222205,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222515,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222570,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222777,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223424,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223697,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Alosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224140,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Azelastine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224248,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dipyridamole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224351,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224481,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224529,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Azathioprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224808,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224938,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225163,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225560,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225894,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225937,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Busulfan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226130,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226265,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226533,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226725,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227644,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227901,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228222,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228339,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228644,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229047,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Fluvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229261,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229584,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230398,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230538,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230851,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefadroxil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231064,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231143,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Amifostine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231230,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefprozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231285,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231387,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231980,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ciclopirox",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232062,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232141,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232473,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232562,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233054,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233330,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233400,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Anastrozole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233605,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233711,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233758,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234376,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234622,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234697,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234790,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234836,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235022,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235084,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Danazol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235393,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Cefepime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235484,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235877,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Calcipotriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236034,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "gamma-Aminobutyric acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236105,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Acetylcysteine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236171,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236406,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236442,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Vitamin D",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236485,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236615,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194857,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195100,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Baclofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195815,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Betaxolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196465,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196721,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196957,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197165,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197166,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Eptifibatide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197167,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197169,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197170,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197171,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Phentermine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197172,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197173,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197174,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197175,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Ticlopidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197176,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Adapalene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197177,
      "ingredient1": "Pantoprazole"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "Coadministration with cholestyramine may decrease the bioavailability and efficacy of deferasirox. The mechanism involves binding of cholestyramine to deferasirox and its glucuronide metabolites, which are secreted into the bile. This interferes with the enterohepatic recycling of deferasirox by preventing intestinal deconjugation of the glucuronide metabolites and subsequent reabsorption. In healthy volunteers, administration of cholestyramine (12 grams twice daily) 4 and 10 hours after a single dose of deferasirox resulted in a 45% decrease in deferasirox systemic exposure (AUC). The interaction has not been studied with other bile acid sequestrants.",
      "management_text": "The concomitant use of deferasirox with cholestyramine should generally be avoided. Otherwise, consideration should be given to increasing the initial dosage of deferasirox by 50% with subsequent adjustments made according to serum ferritin levels and clinical response. It is not known whether other bile acid sequestrants interact similarly with deferasirox.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64754,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.",
      "management_text": "Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64755,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Doxercalciferol",
      "severity": "Moderate",
      "effect": "INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical safety studies, rats administered colesevelam at doses greater than 30-fold the projected human clinical dose developed hemorrhage in association with vitamin K deficiency. In a crossover study involving healthy subjects, coadministration of sevelamer with calcitriol resulted in a significant reduction in bioavailability for calcitriol (calcitriol with sevelamer vs calcitriol alone: AUC 137 pg*h/mL vs 318 pg*h/mL and Cmax 40.1 pg/mL vs 49.7 pg/mL, respectively).",
      "management_text": "Oral vitamin supplements should be administered at least 4 hours before colesevelam and either 1 hour before or 4 to 6 hours after other bile acid sequestrants and sevelamer.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64763,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Esterified estrogens",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64766,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Estrone sulfate",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64768,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Fenofibric acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Theoretically, bile acid sequestrants may bind to and decrease the gastrointestinal absorption of fenofibrate/fenofibric acid.",
      "management_text": "Fenofibrate/fenofibric acid should be taken at least 1 hour before or 4 to 6 hours after the bile acid sequestrant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64771,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Desogestrel",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins.  The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.  Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 292943,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Dienogest",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins.  The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.  Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 298419,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10725,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.",
      "management_text": "Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11124,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration with cholestyramine or colestipol may interfere with the absorption of some hydro-soluble vitamins such as folic acid.",
      "management_text": "Patients on prolonged cholestyramine or colestipol therapy should take folic acid supplements at least 1 hour before or 4 to 6 hours after receiving cholestyramine or colestipol.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14721,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "INTERVAL: Limited data have shown that the bioavailability of orally administered furosemide is reduced by 95% during concurrent administration of cholestyramine and by 80% during concurrent administration of colestipol. (These figures are based on data from the area under the plasma concentration-time curve and total urinary elimination data.) These decreases in bioavailability were associated with 77% and 58% reductions in the diuretic response to furosemide. No data are available for bumetanide, torsemide, or ethacrynic acid, but a similar interaction is suspected.",
      "management_text": "Diuretics should be administered at least 2 to 3 hours before cholestyramine or colestipol. If alternating dosage schedules is ineffective, it may be necessary to increase diuretic dosage during coadministration. Patients should be monitored for altered diuretic efficacy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15513,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Moderate",
      "effect": "INTERVAL: Bile acid sequestrants may bind to and decrease the gastrointestinal absorption of gemfibrozil.",
      "management_text": "Gemfibrozil and bile acid sequestrants should be taken at least 2 hours apart.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15875,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17027,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18503,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Moderate",
      "effect": "INTERVAL: Theoretically, bile acid sequestrants may bind to and decrease the gastrointestinal absorption of fenofibrate/fenofibric acid.",
      "management_text": "Fenofibrate/fenofibric acid should be taken at least 1 hour before or 4 to 6 hours after the bile acid sequestrant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26615,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.",
      "management_text": "Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39066,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Conjugated estrogens",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39568,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Moderate",
      "effect": "INTERVAL: In a study of 40 healthy hypercholesterolemic adults, concomitant administration of cholestyramine (4 g twice daily) decreased the mean area under the plasma concentration-time curve (AUC) of total ezetimibe by approximately 55%. The incremental LDL cholesterol reduction expected with the addition of ezetimibe to cholestyramine or other bile acid sequestrants may be diminished by this interaction.",
      "management_text": "Ezetimibe should be administered at least 2 hours before or 4 hours after the bile acid sequestrant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40492,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Chlorothiazide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63314,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease hypoglycemic effect of some sulfonylureas by decreasing their absorption and enterohepatic recirculation.",
      "management_text": "Sulfonylureas should be administered at least one hour before or four to six hours after cholestyramine. Patients receiving this combination should be advised to closely monitor their blood sugar and to notify their physician if loss of control occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63627,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63984,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Moderate",
      "effect": "Cholestyramine may decrease the absorption and increase the elimination of warfarin or other oral anticoagulants. Anticoagulant effect may be reduced. However, cholestyramine also may impair vitamin K absorption, and the anticoagulant effect of warfarin may be enhanced in some patients. Starting or stopping cholestyramine in the presence of chronic oral anticoagulant therapy may lead to altered PT or INR.",
      "management_text": "Warfarin or other oral anticoagulants should be administered at least one hour before or four to six hours after cholestyramine. The INR or PT should be closely monitored. Patients should be advised to promptly report any signs of bleeding (e.g., pain, swelling, headache, dizziness, weakness, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools) or clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64748,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Moderate",
      "effect": "Cholestyramine may decrease the absorption and increase the elimination of warfarin or other oral anticoagulants. Anticoagulant effect may be reduced. However, cholestyramine also may impair vitamin K absorption, and the anticoagulant effect of warfarin may be enhanced in some patients. Starting or stopping cholestyramine in the presence of chronic oral anticoagulant therapy may lead to altered PT or INR.",
      "management_text": "Warfarin or other oral anticoagulants should be administered at least one hour before or four to six hours after cholestyramine. The INR or PT should be closely monitored. Patients should be advised to promptly report any signs of bleeding (e.g., pain, swelling, headache, dizziness, weakness, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools) or clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64757,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Diethylstilbestrol",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64758,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the absorption and possibly the enterohepatic recirculation of digoxin. Digoxin serum concentrations and pharmacologic effect may be reduced.",
      "management_text": "Cholestyramine should be administered at least eight hours before or after a dose of digoxin. It may be prudent to monitor patients for altered clinical response and to monitor digoxin levels. Patients should be advised to notify their physician if they experience worsening of their heart symptoms. Conversely, patients should be monitored for digoxin toxicity after discontinuation of cholestyramine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64759,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Dihydrotachysterol",
      "severity": "Moderate",
      "effect": "INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical safety studies, rats administered colesevelam at doses greater than 30-fold the projected human clinical dose developed hemorrhage in association with vitamin K deficiency. In a crossover study involving healthy subjects, coadministration of sevelamer with calcitriol resulted in a significant reduction in bioavailability for calcitriol (calcitriol with sevelamer vs calcitriol alone: AUC 137 pg*h/mL vs 318 pg*h/mL and Cmax 40.1 pg/mL vs 49.7 pg/mL, respectively).",
      "management_text": "Oral vitamin supplements should be administered at least 4 hours before colesevelam and either 1 hour before or 4 to 6 hours after other bile acid sequestrants and sevelamer.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64760,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Drospirenone",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64764,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Ergocalciferol",
      "severity": "Moderate",
      "effect": "INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical safety studies, rats administered colesevelam at doses greater than 30-fold the projected human clinical dose developed hemorrhage in association with vitamin K deficiency. In a crossover study involving healthy subjects, coadministration of sevelamer with calcitriol resulted in a significant reduction in bioavailability for calcitriol (calcitriol with sevelamer vs calcitriol alone: AUC 137 pg*h/mL vs 318 pg*h/mL and Cmax 40.1 pg/mL vs 49.7 pg/mL, respectively).",
      "management_text": "Oral vitamin supplements should be administered at least 4 hours before colesevelam and either 1 hour before or 4 to 6 hours after other bile acid sequestrants and sevelamer.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64765,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Limited data have shown that the bioavailability of orally administered furosemide is reduced by 95% during concurrent administration of cholestyramine and by 80% during concurrent administration of colestipol. (These figures are based on data from the area under the plasma concentration-time curve and total urinary elimination data.) These decreases in bioavailability were associated with 77% and 58% reductions in the diuretic response to furosemide. No data are available for bumetanide, torsemide, or ethacrynic acid, but a similar interaction is suspected.",
      "management_text": "Diuretics should be administered at least 2 to 3 hours before cholestyramine or colestipol. If alternating dosage schedules is ineffective, it may be necessary to increase diuretic dosage during coadministration. Patients should be monitored for altered diuretic efficacy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64769,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Etonogestrel",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64770,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.",
      "management_text": "Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64772,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Fluvastatin",
      "severity": "Moderate",
      "effect": "INTERVAL: When administered concomitantly, cholestyramine has been reported to decrease the rate and extent of fluvastatin bioavailability. Other bile acid sequestrants may also decrease the bioavailability of other HMG-CoA reductase inhibitors. The mechanism is most likely due to adsorption of the HMG-CoA reductase inhibitor to the bile acid sequestrant. Separating administration times has been shown to decrease the interaction.",
      "management_text": "If therapy with both agents is necessary, the HMG-CoA reductase inhibitor should be administered at least 4 hours after the bile acid sequestrant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64773,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease hypoglycemic effect of some sulfonylureas by decreasing their absorption and enterohepatic recirculation.",
      "management_text": "Sulfonylureas should be administered at least one hour before or four to six hours after cholestyramine. Patients receiving this combination should be advised to closely monitor their blood sugar and to notify their physician if loss of control occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64774,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease hypoglycemic effect of some sulfonylureas by decreasing their absorption and enterohepatic recirculation.",
      "management_text": "Sulfonylureas should be administered at least one hour before or four to six hours after cholestyramine. Patients receiving this combination should be advised to closely monitor their blood sugar and to notify their physician if loss of control occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64775,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease hypoglycemic effect of some sulfonylureas by decreasing their absorption and enterohepatic recirculation.",
      "management_text": "Sulfonylureas should be administered at least one hour before or four to six hours after cholestyramine. Patients receiving this combination should be advised to closely monitor their blood sugar and to notify their physician if loss of control occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64776,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64777,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64779,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Iopanoic acid",
      "severity": "Minor",
      "effect": "Cholestyramine may bind to oral iodine contrast agents and interfere with diagnostic testing. It is recommended that cholestyramine be discontinued prior to imaging with iodine contrast agents.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64780,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Iopodic acid",
      "severity": "Minor",
      "effect": "Cholestyramine may bind to oral iodine contrast agents and interfere with diagnostic testing. It is recommended that cholestyramine be discontinued prior to imaging with iodine contrast agents.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64781,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 22305,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Minor",
      "effect": "Coadministration of cholestyramine and diclofenac significantly reduces the bioavailability of diclofenac. The clinical significance of this reduction is not clear. Separating the administration of diclofenac and cholestyramine doses may diminish the effects of this interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 53922,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64747,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64753,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64756,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64762,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Minor",
      "effect": "Cholestyramine and colestipol may interfere with the absorption of oral tricyclic antidepressants, resulting in a moderate reduction of antidepressant serum concentrations. The clinical significance is unknown. The effectiveness of tricyclic antidepressants may be reduced. Monitoring the patient for altered therapeutic effects may be advisable. If an interaction is suspected, tricyclic antidepressants should be administered at least two hours before or four to six hours after cholestyramine or colestipol.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64778,
      "ingredient1": "Cholestyramine"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Major",
      "effect": "Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.",
      "management_text": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 107865,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2552,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 4885,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14452,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Amifostine",
      "severity": "Moderate",
      "effect": "Concomitant use with hypotensive agents may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration.",
      "management_text": "If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20741,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22128,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24143,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 27300,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28452,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Phenobarbital",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39951,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Benzhydrocodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41137,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47842,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51278,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54400,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58670,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70818,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71221,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78893,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85423,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87618,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91289,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Moderate",
      "effect": "Additive pharmacodynamic effects may be expected when relatively selective alpha-1A adrenoreceptor antagonists are coadministered with other alpha-blockers. Clinical data have not been reported, but there may be an increased risk and/or severity of adverse effects related to blockade of alpha-1 adrenergic receptors in the peripheral vasculature such as postural hypotension, dizziness, headache, syncope, priapism, and nasal congestion. These effects have occurred with alpha-1A adrenoreceptor antagonists even when given alone for the treatment of benign prostatic hyperplasia, despite relative selectivity for the 1A subtype of alpha-1 adrenoreceptors located in prostatic and bladder tissues.",
      "management_text": "The use of relatively selective alpha-1A adrenoreceptor antagonists in combination with other alpha-blockers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94305,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98125,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Sodium oxybate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 106589,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Chloral hydrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107775,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107777,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107778,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107779,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Fenoldopam",
      "severity": "Moderate",
      "effect": "The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.",
      "management_text": "Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107780,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.",
      "management_text": "Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107784,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107786,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107789,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107790,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107806,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Phenelzine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107841,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107842,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107844,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107845,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107847,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Rasagiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107848,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Remimazolam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107849,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Riociguat",
      "severity": "Moderate",
      "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.",
      "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107850,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107851,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Safinamide",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107852,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107854,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Selexipag",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107855,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Silodosin",
      "severity": "Moderate",
      "effect": "Additive pharmacodynamic effects may be expected when relatively selective alpha-1A adrenoreceptor antagonists are coadministered with other alpha-blockers. Clinical data have not been reported, but there may be an increased risk and/or severity of adverse effects related to blockade of alpha-1 adrenergic receptors in the peripheral vasculature such as postural hypotension, dizziness, headache, syncope, priapism, and nasal congestion. These effects have occurred with alpha-1A adrenoreceptor antagonists even when given alone for the treatment of benign prostatic hyperplasia, despite relative selectivity for the 1A subtype of alpha-1 adrenoreceptors located in prostatic and bladder tissues.",
      "management_text": "The use of relatively selective alpha-1A adrenoreceptor antagonists in combination with other alpha-blockers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107857,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Moderate",
      "effect": "Tadalafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Tadalafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if tadalafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of tadalafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating tadalafil, and tadalafil should be initiated at the lowest recommended dosage. In those patients already on an optimized dosage of tadalafil, alpha blocker therapy should be initiated at the lowest dosage. Clinicians should bear in mind that the safety of tadalafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications. The combination of tadalafil and alpha blockers is not recommended for the treatment of benign prostatic hyperplasia (BPH) due to the lack of safety and efficacy data. Patients on alpha blocker therapy for BPH should discontinue the alpha blocker at least one day prior to starting tadalafil for once-daily use in the treatment of BPH.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107859,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107861,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Thiothixene",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107864,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Tranylcypromine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107866,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107868,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107870,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Trimipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107871,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Moderate",
      "effect": "Vardenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Vardenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if vardenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of vardenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating vardenafil, and vardenafil should be initiated at the lowest recommended dosage (i.e., 5 mg). In those patients already on an optimized dosage of vardenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of vardenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107872,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107874,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5318,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "Additive pharmacodynamic effects may be expected when alfuzosin is coadministered with other alpha-blockers. Clinical data have not been reported, but there may be an increased risk and/or severity of adverse effects related to blockade of alpha-1 adrenergic receptors in the peripheral vasculature such as postural hypotension, dizziness, headache, syncope, priapism, and nasal congestion. These effects have occurred with alfuzosin even when given alone for the treatment of benign prostatic hyperplasia, despite relative selectivity for the 1A subtype of alpha-1 adrenoreceptors located in prostatic and bladder tissues.",
      "management_text": "The use of alfuzosin in combination with other alpha-blockers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16351,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19332,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22629,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Baclofen",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38406,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51705,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52507,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Cabergoline",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52946,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58970,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62724,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69734,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Moderate",
      "effect": "Coadministration of clonidine with other sympatholytic drugs such as alpha-adrenergic blockers may produce additive effects on the sinus and atrioventricular (AV) nodes, potentially causing sinus node dysfunction and AV block. Limited data suggest that the antihypertensive effects of clonidine may be antagonized by prazosin and possibly other alpha-adrenergic blockers. The exact mechanism of interaction is unknown, and data are conflicting.",
      "management_text": "Close clinical monitoring of hemodynamic response and tolerance is recommended if clonidine is prescribed with an alpha-adrenergic blocker, and the dosage of one or both agents adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71520,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71991,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72523,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74090,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Dexmedetomidine has been associated with hypotensive and negative chronotropic effects. Coadministration with other agents causing these effects, especially vasodilators and alpha-2 agonists, may result in additive effects on blood pressure and heart rate.",
      "management_text": "Caution and monitoring of the patient's hemodynamic status are recommended during coadministration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84984,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92338,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105206,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107773,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Butabarbital",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107774,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107776,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107781,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107782,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107785,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107787,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107788,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107791,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107843,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107846,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Secobarbital",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107853,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Moderate",
      "effect": "Sildenafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Sildenafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if sildenafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of sildenafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating sildenafil, and sildenafil should be initiated at the lowest recommended dosage when used for erectile dysfunction (i.e., 25 mg). No dosage adjustment is necessary if used in the treatment of pulmonary arterial hypertension. In those patients already on an optimized dosage of sildenafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of sildenafil in combination with alpha blockers may be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107856,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107860,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Thiethylperazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107862,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107863,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Treprostinil",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107867,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Triflupromazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107869,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Verteporfin",
      "severity": "Moderate",
      "effect": "Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.",
      "management_text": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107873,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107875,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107876,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.",
      "management_text": "Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 252217,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Minor",
      "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107783,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107793,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107795,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107796,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107798,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin human",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107792,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107797,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Minor",
      "effect": "Phentolamine can increase the endogenous secretion of insulin in patients with type II diabetes mellitus. Theoretically, this effect could decrease insulin requirements. However, since phentolamine is usually administered only in single doses, the clinical importance is probably limited. Management consists of carefully monitoring blood glucose after the administration of phentolamine if the situation warrants.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107801,
      "ingredient1": "Phentolamine"
    },
    {
      "ingredient2": "Ganirelix",
      "severity": "Moderate",
      "effect": "Ganirelix can suppress the secretion of pituitary gonadotropins.",
      "management_text": "A dose adjustment may be necessary when exogenous gonadotropins are used during controlled ovarian hyperstimulation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184044,
      "ingredient1": "Follitropin (recombinant fsh)"
    },
    {
      "ingredient2": "Aclidinium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7165,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Umeclidinium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114478,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Belladonna",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158425,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Erdafitinib",
      "severity": "Moderate",
      "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.",
      "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158430,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158432,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Coadministration with gilteritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the intestinal P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or organic cation transporter 1 (OCT1) transporters, such as dabigatran, digoxin, rosuvastatin, methotrexate, and metformin.",
      "management_text": "Until more information is available, caution is advised if gilteritinib is used concomitantly with drugs that are substrates of the intestinal P-gp, BCRP, and/or OCT1 transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever gilteritinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158437,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Moderate",
      "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.",
      "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158441,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Revefenacin",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158446,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Dienogest",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The efficacy of oral contraceptives may be reduced if severe diarrhea occurs with prucalopride treatment.",
      "management_text": "In patients who develop severe diarrhea during treatment with prucalopride, the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception. If severe or persistent diarrhea occurs, patients should be advised to stop taking prucalopride and consult their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179916,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Desogestrel",
      "severity": "Moderate",
      "effect": "The efficacy of oral contraceptives may be reduced if severe diarrhea occurs with prucalopride treatment.",
      "management_text": "In patients who develop severe diarrhea during treatment with prucalopride, the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception.  If severe or persistent diarrhea occurs, patients should be advised to stop taking prucalopride and consult their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293077,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride.  Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300514,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25420,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The efficacy of oral contraceptives may be reduced if severe diarrhea occurs with prucalopride treatment.",
      "management_text": "In patients who develop severe diarrhea during treatment with prucalopride, the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception. If severe or persistent diarrhea occurs, patients should be advised to stop taking prucalopride and consult their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 29778,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Benzatropine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41698,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Biperiden",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44435,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Glycopyrronium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50482,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Clidinium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62873,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 79527,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86208,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87642,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ipratropium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94015,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Trospium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111222,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112380,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Cyclizine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158428,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158429,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158434,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Scopolamine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158449,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Solifenacin",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158451,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158456,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158457,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Trimethobenzamide",
      "severity": "Moderate",
      "effect": "Concomitant administration of anticholinergic agents would be expected to reduce the therapeutic effects of prucalopride. Prucalopride increases bowel motility by stimulating colonic peristalsis (high-amplitude propagating contractions), an action that has been shown to be facilitated by acetylcholine release in isolated gastrointestinal tissues from various animal species.",
      "management_text": "Monitoring for altered efficacy of prucalopride may be advisable during concomitant use with anticholinergic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158458,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10604,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18952,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 34881,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Daclatasvir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 77976,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 96512,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 97181,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Eliglustat",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 97384,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Velpatasvir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 112037,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Istradefylline",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 120910,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158427,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Fidaxomicin",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158433,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158436,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158438,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158440,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Regorafenib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158444,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Rolapitant",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158447,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Sarecycline",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158448,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Suvorexant",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158452,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ticagrelor",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158455,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Tucatinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158459,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ulipristal",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158460,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Valbenazine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158461,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Glecaprevir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 185736,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "This effect is unlikely to be clinically significant.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 247707,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Dasabuvir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "This effect is unlikely to be clinically significant.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 298043,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 21758,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 56044,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 58049,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 59391,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 59925,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 74432,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 75561,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 77171,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 82924,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 92712,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 101079,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Tolvaptan",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 111067,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 118537,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 121126,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Bepridil",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158426,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158431,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158435,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158443,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Reserpine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158445,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Simeprevir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158450,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Telaprevir",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158453,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158454,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Berotralstat",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.",
      "management_text": "This effect is unlikely to be clinically significant.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 256846,
      "ingredient1": "Prucalopride"
    },
    {
      "ingredient2": "Arsenic trioxide",
      "severity": "Moderate",
      "effect": "Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, use of arsenic trioxide during intensive vitamin B12 therapy for the treatment of megaloblastic anemia may potentiate the risk of cardiac arrhythmias such as ventricular tachycardia and torsade de pointes because of the hypokalemia that may develop during the early phase of vitamin B12 therapy due to increasing potassium requirements as normal erythropoiesis is established. Hypokalemia is a known risk factor for ventricular arrhythmias associated with QT interval prolongation.",
      "management_text": "Caution is advised when arsenic trioxide is administered to patients requiring vitamin B12 for severe megaloblastic anemia. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with arsenic trioxide. During therapy, potassium concentrations should be kept above 4 mEq/dL.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31663,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12 in the treatment of anemia.",
      "management_text": "Patients with preexisting anemia should preferably not receive chloramphenicol due to the drug's depressive effect on bone marrow and reticulocytes. If use is unavoidable, the lowest effective dosage of chloramphenicol should be given. Hematologic response to iron or vitamin B12 therapy should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62376,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Dexlansoprazole",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 84789,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6667,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6849,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6985,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 65664,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105566,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Nizatidine",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 145328,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 150688,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Minor",
      "effect": "By reducing or suppressing gastric acid secretion, H2-receptor antagonists and proton pump inhibitors may interfere with the gastrointestinal absorption of vitamin B12, a process that is dependent on the presence of gastric acid and pepsin. Clinical studies have shown that dietary (i.e., protein-bound) vitamin B12 malabsorption can occur during treatment with these agents, particularly proton pump inhibitors, although the likelihood of developing clinically significant deficiency over time is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 179707,
      "ingredient1": "Mecobalamin"
    },
    {
      "ingredient2": "Oxytocin",
      "severity": "Major",
      "effect": "Prostaglandins, especially those of the E type such as misoprostol, may potentiate the uterine response to oxytocin and increase the risk of uterine hyperstimulation and rupture.",
      "management_text": "In the countries where it is indicated for the induction of labor or termination of pregnancy, the use of misoprostol in combination with oxytocin and other oxytocic agents is considered contraindicated (GB).  Infusion of oxytocin should not be started until at least 4 hours after the last dose of misoprostol oral tablet or at least 6 to 12 hours after the insertion of a misoprostol vaginal tablet.  Recommended time intervals vary by brand and manufacturer.  It is recommended to refer to local guidelines or drug product labeling.  As cervical trauma can occur without remarkable symptomatology, each patient should also be carefully examined postabortion.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 263873,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Dinoprostone (topical)",
      "severity": "Major",
      "effect": "The use of other oxytocic agents with dinoprostone may stimulate uterine hypertonus, which can lead to uterine rupture or cervical laceration, particularly in the presence of an undilated or poorly dilated cervix.",
      "management_text": "The concomitant use of dinoprostone with other oxytocic agents is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 86052,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Polyethylene glycol (3350 with electrolytes)",
      "severity": "Moderate",
      "effect": "By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl and gastric irritation and dyspepsia.",
      "management_text": "The administration of antacids and bisacodyl should be separated by at least one hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 258450,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of quinapril with some oral medications may significantly decrease their absorption and may result in subtherapeutic serum concentrations. The proposed mechanism is chelation of the drug by the magnesium hydroxide excipient in quinapril tablets.",
      "management_text": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86056,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sodium citrate",
      "severity": "Minor",
      "effect": "Concomitant administration of antacids can reduce the bioavailability of misoprostol acid, the active metabolite of misoprostol. The mechanism of interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 26244,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Aluminum hydroxide",
      "severity": "Minor",
      "effect": "Concomitant administration of antacids can reduce the bioavailability of misoprostol acid, the active metabolite of misoprostol. The mechanism of interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 86050,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Calcium carbonate",
      "severity": "Minor",
      "effect": "Concomitant administration of antacids can reduce the bioavailability of misoprostol acid, the active metabolite of misoprostol. The mechanism of interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 86051,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sodium bicarbonate",
      "severity": "Minor",
      "effect": "Concomitant administration of antacids can reduce the bioavailability of misoprostol acid, the active metabolite of misoprostol. The mechanism of interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 86057,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Minor",
      "effect": "single case report suggests that concomitant use of naproxen and misoprostol may increase the risk of neurological side effects. Until more data are available, it is recommended that patients be monitored for evidence of increased toxicity during concomitant therapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 102821,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Auranofin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223024,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tegaserod",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223025,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223026,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223074,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223298,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223603,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223746,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223849,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224050,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Desloratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224069,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224330,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224777,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225079,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225287,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225478,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225765,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226448,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226823,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226956,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227156,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227766,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Oxybutynin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228183,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228473,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228607,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228940,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229083,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229512,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229825,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Nifedipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230349,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230671,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230799,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230984,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231522,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231802,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233026,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233233,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233540,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233916,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234055,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234146,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234512,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234941,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235218,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235450,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ursodeoxycholic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235755,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Quazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235791,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235957,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236788,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194428,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194537,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194768,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195009,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195255,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195490,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195610,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195732,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196370,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196440,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196593,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196804,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196906,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197306,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197540,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pregabalin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198021,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198099,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198564,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198769,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199445,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200045,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200224,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Acetaminophen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200950,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201121,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201472,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Atenolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202001,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202242,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202567,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202772,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203044,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203089,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203554,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203805,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204007,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204347,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204509,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pramipexole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204583,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204721,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205032,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205251,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205311,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205502,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205597,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Nabumetone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206855,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207059,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207141,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Raloxifene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207298,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207475,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Dicloxacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207716,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Oxycodone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208140,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208419,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Oxaliplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208667,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208826,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208953,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209127,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209449,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209560,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210128,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210403,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Vinblastine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210495,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210560,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210834,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210949,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210986,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211232,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Nizatidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211378,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211543,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211742,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211993,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212207,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Niacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212604,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212959,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213201,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213376,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Pemetrexed",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213412,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214082,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214459,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214883,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215113,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Nitrofurantoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215281,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215661,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Nitroglycerin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216078,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216186,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216723,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217121,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Potassium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217391,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217998,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218357,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ribavirin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219166,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219319,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219837,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220245,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220369,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220616,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220805,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220892,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Risedronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221373,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221510,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221651,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221879,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222695,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222934,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223020,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Montelukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223021,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223022,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223023,
      "ingredient1": "Misoprostol"
    },
    {
      "ingredient2": "Bethanechol",
      "severity": "Moderate",
      "effect": "Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of direct-acting cholinergic agents such as bethanechol, carbachol, cevimeline, and pilocarpine. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose. Conversely, cholinergic agents may also counteract the pharmacologic effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents). The mechanism of interaction involves opposing pharmacodynamic action on muscarinic receptor sites.",
      "management_text": "It may be appropriate to avoid concomitant use of anticholinergic agents and cholinergic agents, depending on the needs of the patient. If concurrent use is necessary, the patient should be monitored for reduced pharmacologic effects of both drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 42767,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors (e.g., donepezil, galantamine, physostigmine, rivastigmine, tacrine) may antagonize the effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents; class IA antiarrhythmics). By inhibiting the metabolism of acetylcholine, more of the neurotransmitter may be available to compete at muscarinic receptors, the site of action of anticholinergic agents. Conversely, anticholinergic agents may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Anticholinergic agents should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives. Caution is required, however, since anticholinergic withdrawal may occur. Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 90463,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Echothiophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95220,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Demecarium (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114414,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Carbamoylcholine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 56200,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Cevimeline",
      "severity": "Moderate",
      "effect": "Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of direct-acting cholinergic agents such as bethanechol, carbachol, cevimeline, and pilocarpine. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose. Conversely, cholinergic agents may also counteract the pharmacologic effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents). The mechanism of interaction involves opposing pharmacodynamic action on muscarinic receptor sites.",
      "management_text": "It may be appropriate to avoid concomitant use of anticholinergic agents and cholinergic agents, depending on the needs of the patient. If concurrent use is necessary, the patient should be monitored for reduced pharmacologic effects of both drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62005,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors (e.g., donepezil, galantamine, physostigmine, rivastigmine, tacrine) may antagonize the effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents; class IA antiarrhythmics). By inhibiting the metabolism of acetylcholine, more of the neurotransmitter may be available to compete at muscarinic receptors, the site of action of anticholinergic agents. Conversely, anticholinergic agents may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Anticholinergic agents should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives. Caution is required, however, since anticholinergic withdrawal may occur. Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114415,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Isoflurophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114416,
      "ingredient1": "Tropicamide"
    },
    {
      "ingredient2": "Aluminum hydroxide",
      "severity": "Moderate",
      "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60107,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60108,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Dexlansoprazole",
      "severity": "Moderate",
      "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60114,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Indium In-111 oxyquinoline",
      "severity": "Moderate",
      "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.",
      "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60120,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Moderate",
      "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6546,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10696,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15494,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18477,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.",
      "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60111,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Moderate",
      "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60113,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60115,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Moderate",
      "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60116,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Entecavir",
      "severity": "Moderate",
      "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60117,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Moderate",
      "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60118,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60119,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197569,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207509,
      "ingredient1": "Cefditoren"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "INTERVAL: Data are limited with respect to any potential interaction between intranasal esketamine and other nasal products during concomitant administration. In pharmacokinetic studies, mometasone furoate and oxymetazoline hydrochloride administered intranasally one hour before esketamine demonstrated no clinically significant effects on esketamine peak plasma concentration and exposure.",
      "management_text": "To minimize the risk of interaction, patients who require a nasal corticosteroid or nasal decongestant on a day when esketamine dosing is scheduled should administer these medications at least one hour before esketamine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40053,
      "ingredient1": "Beclomethasone dipropionate"
    },
    {
      "ingredient2": "Acitretin",
      "severity": "Major",
      "effect": "Acitretin interferes with the contraceptive effect of microdosed progestin preparations. The mechanism of interaction has not been described, and it is not known whether the effectiveness of implantable or injectable products are affected.",
      "management_text": "Because use of acitretin is associated with major birth defects, microdosed 'minipill' progestin preparations are not recommended for women of childbearing potential treated with acitretin. It is not known whether other progestational contraceptives such as implants and injectables offer adequate contraception during acitretin therapy. Simultaneous use of at least two methods of effective contraception is mandatory during acitretin therapy and for at least 3 years after discontinuing therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 7061,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Major",
      "effect": "Coadministration with some hormonal contraceptives may decrease the plasma concentrations of amprenavir. The mechanism of interaction is unknown.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.e., nonhormonal) methods of birth control should be considered in patients treated with amprenavir.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10659,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with bosentan may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is bosentan induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with bosentan. Because use of bosentan is likely associated with major birth defects, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bosentan. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10678,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Carfilzomib",
      "severity": "Major",
      "effect": "Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent use of hormonal contraception also associated with this adverse effect can potentiate the risk.",
      "management_text": "Hormonal contraception associated with a risk of thrombosis should generally be avoided during use of carfilzomib. Advise female and male patients of reproductive potential to use effective contraception or abstain from sexual activity during treatment with carfilzomib for at least 30 and 90 days, respectively, following completion of therapy. Advise the patient to contact their physician immediately if pregnancy does occur during these times.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10690,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Major",
      "effect": "Some hormonal contraceptives may decrease the plasma concentrations of amprenavir from fosamprenavir when it is administered in the absence of low-dose ritonavir as a pharmacokinetic booster. In contrast, fosamprenavir in combination with ritonavir may reduce the plasma levels of certain contraceptive hormones, and there is also an increased risk of transaminase elevations when these agents are used together. The mechanism of interaction has not been described.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.e., nonhormonal) methods of birth control should be considered in patients treated with fosamprenavir.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10804,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mycophenolate mofetil",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The mechanism of interaction has not been established.",
      "management_text": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10896,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mycophenolic acid",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The mechanism of interaction has not been established.",
      "management_text": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10897,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Oxcarbazepine",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10920,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rifapentine",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with rifampin.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10957,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "St. John's Wort",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with St. John's wort may reduce the efficacy of contraceptive hormones. The exact mechanism of interaction is unknown but may involve reduced absorption as well as accelerated clearance of the hormones due to induction of intestinal P-glycoprotein drug efflux transporter and intestinal/hepatic CYP450 3A4 metabolism by constituents of St. John's wort. There have been case reports of menstrual breakthrough bleeding following the addition of St. John's wort in patients receiving long-term oral contraceptives, and cases of unplanned pregnancies have also been reported.",
      "management_text": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine. Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with St. John's wort. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) St. John's wort therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse). However, there are no data on efficacy, compliance, or side effects of this regimen. For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs. It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10985,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sugammadex",
      "severity": "Major",
      "effect": "RECOMMENDED: Sugammadex may decrease the free plasma concentrations and therapeutic efficacy of hormonal contraceptives.",
      "management_text": "Female patients of reproductive potential receiving hormonal contraceptives (whether oral or non-oral) should use an additional, nonhormonal contraceptive method or backup method of contraception (e.g., condoms and spermicides) for 7 days after sugammadex administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10988,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Telaprevir",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may decrease the plasma concentrations and efficacy of hormonal contraceptives. The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir. Because HCV NS3/4A protease inhibitors must be used in combination with peginterferon alfa and ribavirin, and use of ribavirin has been associated with significant birth defects and fetal death, it is particularly important that patients not become pregnant during treatment. Therefore, systemic hormonal contraceptives should not be relied upon as an effective method of birth control in women of childbearing potential treated with HCV NS3/4A protease inhibitors. Two alternative, effective methods of contraception, which may include intrauterine devices and barrier methods, should be used during HCV NS3/4A protease inhibitor treatment in combination with peginterferon alfa and ribavirin. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Two weeks after completion of HCV NS3/4A protease inhibitor treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control for patients receiving peginterferon alfa and ribavirin.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 11000,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Major",
      "effect": "Coadministration with oral contraceptives may significantly increase the plasma concentrations and pharmacologic effects of tizanidine. The proposed mechanism is inhibition of tizanidine metabolism via CYP450 1A2. The interaction has also been reported with other CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, and rofecoxib.",
      "management_text": "The use of tizanidine in combination with oral contraceptives or other CYP450 1A2 inhibitors should generally be avoided. Caution is advised if concurrent use is clinically necessary. Dosage adjustments may be required in patients who experience excessive adverse effects of tizanidine such as drowsiness, dizziness, lightheadedness, hypotension, bradycardia, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 11016,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Phenobarbital",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39875,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with brigatinib may decrease the plasma concentrations of contraceptive hormones. Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations. Since contraceptive hormones are known substrates of the isoenzyme, decreased concentrations and therapeutic failure may potentially occur.",
      "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with brigatinib. Because use of brigatinib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Alternative or additional methods of birth control (i.e., non-hormonal) are recommended during and for at least 4 months after the final dose of brigatinib. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 48181,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 56431,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 77705,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Major",
      "effect": "Coadministration with encorafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. Although specific pharmacokinetic studies have not been conducted, encorafenib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.",
      "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with encorafenib. Because encorafenib can cause fetal harm, it is particularly important that patients not become pregnant during treatment. Therefore, females of reproductive potential should use an effective, nonhormonal method of contraception during treatment and for 2 weeks after the final dose of encorafenib. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 98958,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lumacaftor",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with lumacaftor may significantly decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is lumacaftor induction of the CYP450 3A4-mediated metabolism of estrogens and progestins.",
      "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, should not be relied upon as an effective method of contraception when coadministered with lumacaftor/ivacaftor. Female patients of childbearing potential should use an alternative or additional method of contraception. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 101453,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rifabutin",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with rifampin.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 105554,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may decrease the plasma concentrations and efficacy of hormonal contraceptives. The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir. Because HCV NS3/4A protease inhibitors must be used in combination with peginterferon alfa and ribavirin, and use of ribavirin has been associated with significant birth defects and fetal death, it is particularly important that patients not become pregnant during treatment. Therefore, systemic hormonal contraceptives should not be relied upon as an effective method of birth control in women of childbearing potential treated with HCV NS3/4A protease inhibitors. Two alternative, effective methods of contraception, which may include intrauterine devices and barrier methods, should be used during HCV NS3/4A protease inhibitor treatment in combination with peginterferon alfa and ribavirin. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Two weeks after completion of HCV NS3/4A protease inhibitor treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control for patients receiving peginterferon alfa and ribavirin.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126501,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126504,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126507,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126509,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Griseofulvin",
      "severity": "Major",
      "effect": "RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance of the hormones due to induction of hepatic CYP450 enzymes by griseofulvin.",
      "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with griseofulvin. Because griseofulvin has been shown to be teratogenic in animal studies and is capable of inducing aneuploidy (abnormal segregation of chromosomes following cell division) in mammalian cells in vitro and in vivo, it is particularly important that patients not become pregnant during treatment. Therefore, additional methods of birth control should be used during and for one month after griseofulvin therapy. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126515,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pexidartinib",
      "severity": "Major",
      "effect": "Coadministration with pexidartinib may decrease the plasma concentration and efficacy of contraceptive hormones. The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with pexidartinib. Alternative or additional methods of birth control should be used during and for at least one month after the final dose of pexidartinib. In addition, male patients with female partners of reproductive potential should use effective contraception during and for at least one week after the final dose of pexidartinib. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126536,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Primidone",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126541,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with rifampin.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126542,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Major",
      "effect": "RECOMMENDED: There are no data concerning the potential effect of bexarotene on hormonal contraceptives. Presumably, coadministration with bexarotene may decrease the efficacy of contraceptives containing low-dose estrogens and progestins due to its induction of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with bexarotene. Because use of bexarotene is likely associated with major birth defects, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bexarotene.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10676,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tranexamic acid",
      "severity": "Major",
      "effect": "There are no clinical data on the use of tranexamic acid in combination with hormonal contraceptives. Because tranexamic acid is an antifibrinolytic agent, concomitant use may further exacerbate the risk of thrombotic events, including venous thromboembolism as well as arterial thromboses such as stroke and myocardial infarction, associated with hormonal contraceptives. The risk is of particular concern in women who are obese or cigarette smokers, especially smokers over the age of 35. Women using hormonal contraception were generally excluded from clinical trials supporting the safety and efficacy of tranexamic acid for the treatment of menorrhagia (heavy menstrual bleeding). However, there have been postmarketing reports of venous and arterial thrombotic events in women who have used tranexamic acid during treatment with combination hormonal contraceptives.",
      "management_text": "Due to the potential for increased risk of thrombosis in women receiving hormonal contraceptives, the use of tranexamic acid for the treatment of menorrhagia in this population is considered contraindicated. Patients receiving hormonal contraceptives should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 101763,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 126538,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Abametapir (topical)",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations. The proposed mechanism is high and prolonged systemic exposure to the metabolite abametapir carboxyl, which has been shown to be an in vitro inhibitor of CYP450 3A4, CYP450 2B6, and CYP450 1A2.",
      "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion. If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 688,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Aprepitant",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Aprepitant and its prodrug, fosaprepitant, may reduce the efficacy of low-dose hormonal contraceptives during and for up to 28 days after treatment. The proposed mechanism is aprepitant induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of contraceptive hormones.",
      "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant. Alternative or additional methods of birth control is recommended during treatment with aprepitant and for one month following the last dose of aprepitant. Data are not available for single-dosing of aprepitant 40 mg. However, since the timing of aprepitant administration relative to ovulation could cause contraceptive failure, the same precaution as for the 125 mg/80 mg regimen should be observed. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10664,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Moderate",
      "effect": "Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.",
      "management_text": "The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10685,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10686,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10687,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10719,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones. The exact mechanism of interaction has not been described. Clinical effects of increased progestogen levels are not fully known, but may include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis.",
      "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis. Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended. Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. However, the long term effects of increased progesterone exposure are not known. Alternative, nonhormonal methods of contraception may be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10739,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Colestipol",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10741,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10751,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Moderate",
      "effect": "Coadministration with darunavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by darunavir.",
      "management_text": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darunavir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10753,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme.",
      "management_text": "Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10754,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with deferasirox may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is deferasirox induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Hormonal contraceptives agents may not be reliable when used with deferasirox. Female patients of reproductive potential receiving hormonal contraceptives should be counseled to use alternative or additional methods of birth control during treatment with deferasirox.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10755,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Echinacea",
      "severity": "Moderate",
      "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.",
      "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10774,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "RECOMMENDED: There are limited data concerning the potential effect of efavirenz on hormonal contraceptives. Presumably, coadministration with efavirenz may decrease the efficacy of contraceptives containing low-dose estrogens and progestins due to its induction of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Because the potential interaction between efavirenz and contraceptive hormones has not been fully characterized, and use of efavirenz has been associated with fetal malformations in animal studies, the manufacturer recommends that women avoid pregnancy during efavirenz treatment and that a barrier form of contraception be used in addition to hormonal contraceptives. Alternative or additional methods of birth control should be used during and for at least 4 weeks after efavirenz therapy. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10775,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Elvitegravir",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones. The exact mechanism of interaction has not been described. Clinical effects of increased progestogen levels are not fully known, but may include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis.",
      "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis. Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended. Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. However, the long term effects of increased progesterone exposure are not known. Alternative, nonhormonal methods of contraception may be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10778,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10788,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Exenatide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10796,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Moderate",
      "effect": "Concomitant use of hormonal contraceptives has been associated with increased adverse effects of flibanserin. The mechanism of interaction has not been established, but may partially involve inhibition of flibanserin metabolism. Flibanserin is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. Some oral contraceptives are considered weak inhibitors of these isoenzymes.",
      "management_text": "Caution is advised when flibanserin is used with hormonal contraceptives. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10799,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Aprepitant and its prodrug, fosaprepitant, may reduce the efficacy of low-dose hormonal contraceptives during and for up to 28 days after treatment. The proposed mechanism is aprepitant induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of contraceptive hormones.",
      "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant. Alternative or additional methods of birth control is recommended during treatment with aprepitant and for one month following the last dose of aprepitant. Data are not available for single-dosing of aprepitant 40 mg. However, since the timing of aprepitant administration relative to ovulation could cause contraceptive failure, the same precaution as for the 125 mg/80 mg regimen should be observed. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10805,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Glycerol phenylbutyrate",
      "severity": "Moderate",
      "effect": "Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.",
      "management_text": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10816,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10830,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10832,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Moderate",
      "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.",
      "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10845,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Linagliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10861,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Liraglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10866,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Methylphenobarbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10876,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Miltefosine",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The vomiting and/or diarrhea that commonly occur during miltefosine therapy may affect the absorption of oral contraceptives, potentially compromising their efficacy.",
      "management_text": "Female patients receiving oral contraceptives should be advised to use additional non-hormonal or alternative method(s) of effective contraception if vomiting or diarrhea occurs during miltefosine therapy. This is particularly important because miltefosine may cause fetal harm. Teratogenicity and fetal death were observed in animals administered miltefosine at dosages lower than the recommended human dosage. Females of reproductive potential should use effective contraception during miltefosine therapy and for 5 months after completion of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10890,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mitotane",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10893,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Modafinil",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other contraceptive hormones. The mechanism involves induction of CYP450 3A4-mediated metabolism by modafinil and armodafinil.",
      "management_text": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil. Alternative or additional methods of birth control are recommended during and for one month after treatment with modafinil or armodafinil. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10894,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nateglinide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10901,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nefazodone",
      "severity": "Moderate",
      "effect": "Coadministration with nefazodone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nefazodone.",
      "management_text": "Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. A lower initial dosage, as well as clinical and laboratory monitoring, may be appropriate for some drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10902,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Neratinib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with neratinib may reduce the efficacy of hormonal contraceptives. The mechanism for the potential interaction has not been established.",
      "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with neratinib and for up to 1 month after discontinuing treatment. Women using hormonal contraceptives should add a barrier method. In addition, men receiving neratinib should use a barrier method of contraception during treatment and for 3 months after discontinuing treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10905,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Oxtriphylline",
      "severity": "Moderate",
      "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.",
      "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10921,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Perampanel",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants, such as rufinamide and perampanel, may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity by the anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants. In general, alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10930,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with pitolisant may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is induction of the CYP450 3A4-mediated metabolism of estrogens and progestins by pitolisant and its main metabolites.",
      "management_text": "The manufacturer recommends that alternative, nonhormonal methods of effective contraception should be used during and for at least 21 days after pitolisant therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10938,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with pralsetinib may render hormonal contraceptives ineffective. The mechanism for the potential interaction has not been established and there are no clinical data regarding the use of pralsetinib with hormonal contraceptives. Pralsetinib can cause fetal harm when administered to a pregnant woman.",
      "management_text": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 2 weeks after the final dose. In addition, men receiving pralsetinib should use effective contraception during treatment and for 1 week after the final dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10944,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pramlintide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10945,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Prucalopride",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The efficacy of oral contraceptives may be reduced if severe diarrhea occurs with prucalopride treatment.",
      "management_text": "In patients who develop severe diarrhea during treatment with prucalopride, the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception. If severe or persistent diarrhea occurs, patients should be advised to stop taking prucalopride and consult their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10951,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rilonacept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10958,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10963,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rufinamide",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants, such as rufinamide and perampanel, may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity by the anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants. In general, alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10966,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Moderate",
      "effect": "Coadministration with saquinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by saquinavir.",
      "management_text": "Caution is advised if saquinavir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever saquinavir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10967,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sarilumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10969,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Saxagliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10972,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Secukinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10974,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Semaglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10977,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Siltuximab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10978,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Moderate",
      "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.",
      "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10979,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sitagliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10980,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Somatrem",
      "severity": "Moderate",
      "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10982,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tazemetostat",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with tazemetostat may decrease the plasma concentrations and efficacy of hormonal contraceptives. The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Although the clinical significance of the interaction is unknown, caution is advised when tazemetostat is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of tazemetostat may cause fetal harm, it is particularly important that female patients not become pregnant during treatment. Females of reproductive potential should be advised to use alternative or additional methods of birth control during treatment with tazemetostat and for 6 months after the final dose. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10997,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Moderate",
      "effect": "Coadministration with telithromycin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telithromycin.",
      "management_text": "Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telithromycin is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11001,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tocilizumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11018,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ulipristal",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with ulipristal may reduce the efficacy of combination hormonal contraceptives. There are no clinical data regarding use of ulipristal with regular hormonal contraceptives. However, due to its high-affinity binding to the progesterone receptor, ulipristal may interfere with the pharmacologic action of progestogens.The concomitant use of ulipristal and emergency contraception containing levonorgestrel is not recommended.",
      "management_text": "After emergency contraception with ulipristal, routine contraception should be continued or initiated as soon as possible to ensure ongoing prevention of pregnancy. Patients who receive contraceptives containing levonorgestrel or other progestogens should also use a reliable barrier method of contraception until their next menstrual period.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11031,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ustekinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11032,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Albiglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11898,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Alogliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17858,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24036,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Apalutamide",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 27641,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Armodafinil",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other contraceptive hormones. The mechanism involves induction of CYP450 3A4-mediated metabolism by modafinil and armodafinil.",
      "management_text": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil. Alternative or additional methods of birth control are recommended during and for one month after treatment with modafinil or armodafinil. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31368,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Artemether",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine. Alternative or additional methods of birth control should be used. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31930,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Asparaginase Erwinia chrysanthemi",
      "severity": "Moderate",
      "effect": "Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.",
      "management_text": "The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33620,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Atazanavir",
      "severity": "Moderate",
      "effect": "Coadministration with atazanavir may increase the plasma concentrations of ethinyl estradiol and norethindrone and possibly other contraceptive hormones. The mechanism is atazanavir inhibition of CYP450 3A4 and UGT1A1, the enzymes responsible for the metabolic clearance of contraceptive hormones.",
      "management_text": "The manufacturer recommends alternate methods of nonhormonal contraception during atazanavir or atazanavir-ritonavir therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34583,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Bazedoxifene",
      "severity": "Moderate",
      "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated. Safety and efficacy of this combination are unknown.",
      "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus. Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39651,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cenobamate",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60769,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63761,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cholestyramine",
      "severity": "Moderate",
      "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins. The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine. In addition, it has also been suggested that bile-acid binding resins may interfere with the enterohepatic recycling of estrogens and therefore increase their elimination.",
      "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam. Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64783,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67893,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Colesevelam",
      "severity": "Moderate",
      "effect": "INTERVAL: Colesevelam may decrease the gastrointestinal absorption of contraceptive hormones.",
      "management_text": "Oral contraceptives containing ethinyl estradiol and norethindrone should be administered at least 4 hours before the colesevelam dose. The same precaution may be applicable to other contraceptive hormones, although data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73567,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Moderate",
      "effect": "Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.",
      "management_text": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74364,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Coadministration with dronedarone may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter.",
      "management_text": "Caution is advised when dronedarone is used concomitantly with drugs that are substrates of CYP450 2D6, CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dronedarone is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92576,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Dulaglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93489,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Duvelisib",
      "severity": "Moderate",
      "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.",
      "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94485,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96447,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Elexacaftor",
      "severity": "Moderate",
      "effect": "Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.",
      "management_text": "Monitor for rash in patients taking both medications. Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97101,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Emapalumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97914,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98050,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Enasidenib",
      "severity": "Moderate",
      "effect": "Coadministration with enasidenib may alter the plasma concentrations of hormonal contraceptives. In vitro, enasidenib has been found to both inhibit and induce CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of contraceptive hormones. The clinical significance is unknown.",
      "management_text": "Because use of enasidenib may be associated with fetal harm, it is important that patients not become pregnant during treatment. It may be advisable to monitor patients for potentially altered effects of their hormonal contraceptive during and after treatment with enasidenib. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98830,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with ritonavir may decrease the plasma concentrations of contraceptive hormones. The exact mechanism of interaction is unknown but may involve ritonavir induction of glucuronosyltransferase and/or CYP450 hydroxylation. Since estrogens and progestins may share common routes of metabolism, the possibility of a similar interaction should be considered in patients receiving contraceptive hormones other than ethinyl estradiol.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with ritonavir. Alternative or additional methods of birth control should be used during and for at least 4 weeks after ritonavir therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse). However, there are no data on efficacy, compliance, or side effects of this regimen. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100923,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Netupitant",
      "severity": "Moderate",
      "effect": "Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103747,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109759,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tipiracil",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established. Trifluridine is an antineoplastic agent and may cause fetal harm when administered during pregnancy. Data evaluating the interaction are not available.",
      "management_text": "Because trifluridine may cause fetal harm, it is particularly important that patients not become pregnant during tipiracil-trifluridine treatment. Female patients of childbearing potential using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant tipiracil-trifluridine treatment. The manufacturer recommends use of additional barrier contraceptive methods during and for up to 6 months after tipiracil-trifluridine therapy. No recommendations are available for women using hormone-release intrauterine systems or injectable progestin-only contraceptives. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114163,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116084,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lixisenatide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116461,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116570,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Moderate",
      "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp). The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.",
      "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119545,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 121045,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Acetohexamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126498,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Aminophylline",
      "severity": "Moderate",
      "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.",
      "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126499,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Berotralstat",
      "severity": "Moderate",
      "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.",
      "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126500,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with entrectinib may render systemic hormonal contraceptives ineffective. The mechanism for the potential interaction has not been established and there are no clinical data regarding the use of entrectinib with hormonal contraceptives. Physiologically based pharmacokinetic simulation does not predict a significant effect of entrectinib on the pharmacokinetics of ethinyl estradiol. Entrectinib can cause fetal harm when administered to a pregnant woman.",
      "management_text": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 5 weeks after the final dose. In addition, men receiving entrectinib should use highly effective contraceptive methods during treatment and for 3 months after the final dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126502,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126503,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Moderate",
      "effect": "Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.",
      "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126506,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.",
      "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126510,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126512,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126513,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126514,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Guselkumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126516,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lomitapide",
      "severity": "Moderate",
      "effect": "Coadministration with weak inhibitors of CYP450 3A4 including oral contraceptives may increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme. Weak CYP450 3A4 inhibitors increase lomitapide exposure by approximately 2-fold according to the product labeling.",
      "management_text": "The maximum recommended dosage of lomitapide is 30 mg daily when used in combination with weak CYP450 3A4 inhibitors including oral contraceptives. Likewise, if oral contraceptives are initiated during treatment with lomitapide, the dosage of lomitapide may require adjustment. Patients should be advised that hormone absorption from oral contraceptives may be incomplete if vomiting or diarrhea occurs while taking lomitapide, which would warrant the use of additional contraceptive methods, especially since lomitapide may be teratogenic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126525,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lonafarnib",
      "severity": "Moderate",
      "effect": "Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.",
      "management_text": "Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126526,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lorlatinib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126527,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Metreleptin",
      "severity": "Moderate",
      "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.",
      "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126528,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Miconazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126529,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mifepristone",
      "severity": "Moderate",
      "effect": "Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal contraceptives.",
      "management_text": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, only nonhormonal contraceptive methods should be used. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126530,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Miglitol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126531,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nafcillin",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126532,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nilotinib",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.",
      "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126533,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Olaparib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with olaparib may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is olaparib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.",
      "management_text": "Some authorities recommend that women avoid pregnancy during olaparib treatment due to its potential teratogenic effects. In women of childbearing potential, alternative or additional non-hormonal methods of birth control should be considered during treatment and for one month after receiving the last dose of olaparib. Regular pregnancy tests are also recommended. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126534,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Limited clinical data suggest that phenylbutazone may reduce the efficacy of contraceptive hormones, potentially resulting in menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) or unintended pregnancy. The proposed mechanism is accelerated clearance of the hormones due to induction of hepatic CYP450 enzymes by phenylbutazone.",
      "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with phenylbutazone. Alternative or additional methods of birth control should be used during and probably for at least one week after short-term and up to one month after long-term (greater than 4 weeks) phenylbutazone therapy. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126537,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126540,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Satralizumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126543,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Secobarbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126544,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Moderate",
      "effect": "The use of oral contraceptives or hormone replacement therapy may significantly increase selegiline bioavailability.The proposed mechanism is inhibition of CYP450 3A hepatic metabolism. Increased concentrations of selegiline may result in loss of MAO-B selectivity and potentially severe adverse effects such as the serotonin syndrome.",
      "management_text": "Monitoring for signs and symptoms of selegiline toxicity such as excessive MAO inhibition and hypertension when female sex steroids are added and monitoring for reduced selegiline effectiveness when steroids are withdrawn is recommended. Selegiline dosage and dietary adjustments (avoiding tyramine) may be required. Patients should be advised to notify their physician promptly if they experience symptoms such as severe headache, dizziness, nervousness, weakness, irritability, altered consciousness, seizures, confusion, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126545,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Moderate",
      "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.",
      "management_text": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126546,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Somapacitan",
      "severity": "Moderate",
      "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126547,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Stiripentol",
      "severity": "Moderate",
      "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.",
      "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126549,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sulfinpyrazone",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126550,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.",
      "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126551,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Telotristat ethyl",
      "severity": "Moderate",
      "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.",
      "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126552,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Moderate",
      "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.",
      "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126553,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Moderate",
      "effect": "Coadministration with teriflunomide may increase the plasma concentrations of contraceptive hormones. The mechanism of interaction has not been described.",
      "management_text": "Caution is advised if teriflunomide is prescribed in patients receiving hormonal contraceptives due to the potential for increased adverse effects such as thromboembolism. Consideration should be given to the type or dose of contraceptives used in combination with teriflunomide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126554,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126556,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126557,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126558,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126559,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fosnetupitant",
      "severity": "Moderate",
      "effect": "Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191083,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Osilodrostat",
      "severity": "Moderate",
      "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.",
      "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 241974,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Selumetinib",
      "severity": "Moderate",
      "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.",
      "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 241977,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tivozanib",
      "severity": "Moderate",
      "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.",
      "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 241981,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Acarbose",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3168,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 9263,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Alefacept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10647,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Aminoglutethimide",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10652,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Asparaginase Escherichia coli",
      "severity": "Moderate",
      "effect": "Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.",
      "management_text": "The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10668,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Butabarbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10682,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Butalbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10683,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.",
      "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10729,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with clobazam, a weak inducer of CYP450 3A4, may decrease the plasma concentrations of contraceptive hormones.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with clobazam. Additional, nonhormonal forms of contraception should be used during and for 28 days after discontinuing clobazam treatment to ensure contraceptive reliability. A significant interaction with hormone-releasing intrauterine systems is not anticipated due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10732,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10736,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Moderate",
      "effect": "A case report suggests that estrogens or progestins may decrease the serum concentrations and pharmacologic effects of valproic acid (VPA). The proposed mechanism is induction of hepatic glucuronidation by sex hormones.",
      "management_text": "Pharmacologic response and serum valproic levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the valproic acid dosage adjusted as necessary. Patients should be advised to contact their physician if they experience loss of seizure control or symptoms of valproic acid toxicity such as tremors, ataxia, nystagmus, increased seizures, and changes in mental status. In patients receiving oral contraceptives, gradual transient increases in valproic acid levels will likely occur during the pill-free week for women not also taking an enzyme-inducing drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, rifampin). The increase in valproic acid levels will be greater if the dose of valproic acid is increased in the few days before or during the pill-free week.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10767,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.",
      "management_text": "Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10803,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin human (inhalation, rapid acting)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10836,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10838,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nelfinavir",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Nelfinavir may decrease the plasma concentrations of contraceptive hormones during chronic coadministration. The proposed mechanism is nelfinavir induction of the hepatic metabolism of sex hormones.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with nelfinavir. Alternative or additional methods of birth control should be used during and for at least 4 weeks after nelfinavir therapy.If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse). However, there are no data on efficacy, compliance, or side effects of this regimen.No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10903,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nevirapine",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with nevirapine may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is nevirapine induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with nevirapine. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) nevirapine therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse). No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10907,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pegaspargase",
      "severity": "Moderate",
      "effect": "Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.",
      "management_text": "The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10924,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Troglitazone",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with troglitazone may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is troglitazone induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with troglitazone. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) troglitazone therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary. For levonorgestrel emergency contraception in patients receiving enzyme-inducing therapy, a regimen consisting of a 1.5 mg dose as soon as possible (within 72 hours of unprotected intercourse) followed by a 0.75 mg or 1.5 mg dose twelve hours later has been recommended by some clinicians. An alternative is a single 2.25 mg dose as soon as possible following unprotected intercourse. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11027,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Metformin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18103,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25132,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Coadministration with diltiazem may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by diltiazem.",
      "management_text": "Caution is advised if diltiazem must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever diltiazem is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57911,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Limited data suggest that coadministration with contraceptive hormones may increase the plasma concentrations of clozapine. The exact mechanism of interaction is unknown but may involve inhibition of clozapine metabolism via CYP450 1A2, 2C19 and/or 3A4.",
      "management_text": "Patients treated concomitantly with hormonal contraceptives may require a lower dosage of clozapine to control psychotic symptoms. Pharmacologic response to clozapine should be monitored more closely whenever an oral contraceptive is added to or withdrawn from therapy in patients stabilized on their existing antipsychotic regimen, and the clozapine dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72371,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine. The risk of cyclosporine-induced nephrotoxicity, hepatotoxicity, and neurotoxicity may be increased. The proposed mechanism is competitive inhibition of cyclosporine metabolism via CYP450 3A4, of which estrogens and progestins are also substrates.",
      "management_text": "Caution is advised during concomitant therapy with cyclosporine. Cyclosporine blood levels as well as renal and hepatic function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity (e.g., fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, jaundice) or neurotoxicity (e.g., tremor, convulsions).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77046,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95613,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Theophylline",
      "severity": "Moderate",
      "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.",
      "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97512,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108089,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116299,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126505,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.",
      "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126508,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126518,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pentobarbital",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126535,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Somatotropin",
      "severity": "Moderate",
      "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.",
      "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 126548,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Isotretinoin",
      "severity": "Moderate",
      "effect": "Isotretinoin may decrease the plasma concentrations of contraceptive progestins.  The potential mechanism of interaction has not been established.",
      "management_text": "The manufacturers caution that microdosed progesterone-only preparations (\"minipills\") may not be an adequate method of contraception during isotretinoin therapy and should not be used.  Combination oral contraceptive pills are considered an acceptable primary form of contraception and may be used (please refer to the product labeling for list of acceptable primary and secondary forms of contraception).  Due to the teratogenic risk of isotretinoin, females of reproductive potential must use two methods of effective contraception, at least one of which must be a primary form, for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month after discontinuing therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 237850,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Minor",
      "effect": "The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory. The mechanism may be due to enzyme inhibition. Consider counseling women about this interaction which is unpredictable.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10793,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Minor",
      "effect": "Coadministration with etravirine may slightly increase the plasma concentrations of ethinyl estradiol. The mechanism of interaction has not been described.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10794,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Naratriptan",
      "severity": "Minor",
      "effect": "Oral contraceptives (active ingredients not specified) have been reported to decrease the clearance of naratriptan by 32%. Slightly higher serum concentrations have resulted. The mechanism and clinical significance are unknown. The clinician should be aware that the risk of side effects associated with naratriptan is increased if these drugs are given together.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10900,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Minor",
      "effect": "Coadministration with rosuvastatin may increase the plasma concentrations of certain oral contraceptive hormones. The mechanism of interaction has not been established. The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive doses.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10964,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Minor",
      "effect": "Coadministration with atorvastatin may increase the plasma concentrations of estrogens and progestins. The exact mechanism of interaction is unknown but may be related to competitive inhibition of CYP450 3A4, the isoenzyme responsible for the metabolism of atorvastatin, estrogens, some (if not all) progestins, and other steroids. The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive and hormone replacement doses.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 35843,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Brivaracetam",
      "severity": "Minor",
      "effect": "Coadministration with brivaracetam at higher than recommended dosages may decrease the plasma concentrations of contraceptive hormones. The mechanism may involve weak induction of CYP450 3A4 metabolism by brivaracetam. Based on existing data, the interaction is not expected to be clinically relevant, and no particular precaution appears necessary when brivaracetam is used with oral contraceptives.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 49261,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Minor",
      "effect": "Serum concentrations and effects of medications that are metabolized by the 3A4 enzymatic pathways may theoretically be elevated in patients receiving delavirdine. The mechanism is inhibition of these enzymes by delavirdine. Monitoring for clinical and laboratory evidence of safety and tolerance is recommended. Dosage adjustments or alternatives may be needed if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 82843,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Frovatriptan",
      "severity": "Minor",
      "effect": "The concurrent use of oral contraceptives may increase the plasma concentrations of frovatriptan. The mechanism of interaction has not been established, and it is not known if hormonal contraceptives delivered by other routes (intravaginal, transdermal) may similarly affect the pharmacokinetics of frovatriptan. Regardless, this interaction is unlikely to be of clinical significance.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 126511,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Minor",
      "effect": "Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is induction of hormone metabolism via CYP450 3A4.There are no data on the use of contraceptive hormones with pioglitazone. Because pioglitazone may be a weak inducer of CYP450 3A4, product labeling recommends additional caution in women requiring contraception.Intrauterine systems are unlikely to be significantly affected because of their local action.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 126539,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ticagrelor",
      "severity": "Minor",
      "effect": "Coadministration of ethinyl estradiol and levonorgestrel with ticagrelor increased the ethinyl estradiol systemic exposure (AUC) by approximately 20%, but did not alter the pharmacokinetics of levonorgestrel. No clinically relevant effect on oral contraceptive efficacy is expected when ethinyl estradiol and/or levonorgestrel are coadministered with ticagrelor.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 126555,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Minor",
      "effect": "Coadministration with indinavir may increase the plasma concentrations of estrogens and progestins. The proposed mechanism is indinavir inhibition of CYP450 3A4, the isoenzyme involved in the metabolism of estrogens, some (if not all) progestins, and other steroids. The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive and hormone replacement doses.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 126517,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Zolmitriptan",
      "severity": "Minor",
      "effect": "Retrospective pharmacokinetic analysis indicate that plasma concentrations of zolmitriptan may be higher in females taking concurrent oral contraceptives. The mechanism and clinical significance are unknown. The effect of zolmitriptan on the pharmacokinetics of oral contraceptives has not been reported. Patients should be advised to notify their physician promptly if they experience sedation, dizziness, paresthesia, chest pain or tightness, shortness of breath, or irregular heartbeats.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 126560,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Progesterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203116,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203117,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203118,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203119,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Montelukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203120,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203121,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Oxycodone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203122,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Propylthiouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203123,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203124,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203125,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203126,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203127,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203128,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203129,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sevelamer",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203130,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sumatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203131,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203132,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203133,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203134,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Potassium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203135,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203136,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203137,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Misoprostol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203138,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203139,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Orlistat",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203140,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203141,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203142,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203143,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Aripiprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203144,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Varenicline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203145,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203146,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203163,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203924,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204233,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Levothyroxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206057,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Loratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206543,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207006,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207779,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209033,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209743,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Methotrexate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209899,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210252,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211137,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211444,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213989,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Norethisterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215719,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lisinopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215790,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216246,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217874,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mefenamic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218090,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218178,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218538,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219230,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219729,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Metronidazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222326,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222592,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223157,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223459,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224965,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225390,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225602,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226555,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226749,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227043,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227671,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228366,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229641,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230050,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Nifedipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230286,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231416,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233790,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lorazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196192,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197439,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Mesalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198200,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198657,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Metoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199126,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Liothyronine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199597,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Lidocaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199745,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200144,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Acetaminophen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200729,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201290,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202439,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203106,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203107,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Phentermine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203108,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203109,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203110,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203111,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203112,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203113,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Olanzapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203114,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203115,
      "ingredient1": "Levonorgestrel"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115554,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115770,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116057,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116543,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 120649,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Ivabradine",
      "severity": "Major",
      "effect": "Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong the QT interval.",
      "management_text": "Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 121273,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 147805,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Major",
      "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185251,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Major",
      "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.",
      "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185255,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Major",
      "effect": "Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185261,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 11218,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Major",
      "effect": "Anagrelide can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided. Patients receiving anagrelide should have a cardiovascular examination, including an ECG, prior to initiation of treatment and monitored for cardiovascular effects during treatment. Hypokalemia or hypomagnesemia must be corrected prior to therapy and electrolytes monitored periodically during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 15893,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 108046,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116273,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin human (isophane)",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116762,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Major",
      "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.",
      "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185213,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185246,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185247,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Major",
      "effect": "Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185252,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Ibutilide",
      "severity": "Major",
      "effect": "Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185258,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185268,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Inotuzumab ozogamicin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115317,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Iron",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185226,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185243,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Moderate",
      "effect": "Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185245,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Glycerin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185248,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Halothane",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185253,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Histrelin",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185254,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185259,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Indacaterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185263,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Indium In-111 oxyquinoline",
      "severity": "Moderate",
      "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.",
      "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185264,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Iron protein succinylate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185272,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10271,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Isoprenaline",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120113,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185212,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185249,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185250,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185257,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Certain quinolones, including gemifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if gemifloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of gemifloxacin, the recommended dosage should not be exceeded, especially in patients with renal or hepatic impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185262,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185265,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Isoetharine",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185273,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 185260,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 119172,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 185256,
      "ingredient1": "Gemifloxacin"
    },
    {
      "ingredient2": "Dinoprostone (topical)",
      "severity": "Major",
      "effect": "The use of other oxytocic agents with dinoprostone may stimulate uterine hypertonus, which can lead to uterine rupture or cervical laceration, particularly in the presence of an undilated or poorly dilated cervix.",
      "management_text": "The concomitant use of dinoprostone with other oxytocic agents is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 87318,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Bisacodyl",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44666,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54481,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iothalamic acid",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74633,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78969,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84263,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98208,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118937,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120797,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Vilazodone",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176122,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Vortioxetine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176596,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179168,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Coadministration with other medications that can lower serum sodium levels such as diuretics, selective serotonin reuptake inhibitors (SSRIs), and serotonin-noradrenaline reuptake inhibitors (SNRIs) may potentiate the risk of hyponatremia associated with eslicarbazepine.",
      "management_text": "Routine monitoring of serum sodium and chloride levels should be considered during maintenance treatment with eslicarbazepine acetate and concomitant use of other medications known to decrease serum sodium levels. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Depending on the severity of hyponatremia, dosage reduction or discontinuation of eslicarbazepine acetate and other medications may be required, and appropriate medical intervention instituted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179555,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Glycerin",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188905,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Frangula purshiana bark",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189919,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Castor oil",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189952,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192867,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Ioxilan",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192951,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iodipamide",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 194244,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67253,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Diatrizoate",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77444,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93953,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Moderate",
      "effect": "The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.",
      "management_text": "Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 104252,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 147908,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Vasopressin",
      "severity": "Moderate",
      "effect": "The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.",
      "management_text": "Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175425,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175881,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179361,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Exenatide",
      "severity": "Moderate",
      "effect": "Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide. The mechanism of interaction is unknown. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.",
      "management_text": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181452,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Fenoldopam",
      "severity": "Moderate",
      "effect": "The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.",
      "management_text": "Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182091,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183461,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184038,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 194245,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Minor",
      "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 191237,
      "ingredient1": "urea"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.",
      "management_text": "The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 14774,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Major",
      "effect": "Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity.",
      "management_text": "Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 15865,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Major",
      "effect": "Coadministration with boceprevir may significantly increase the plasma concentrations of atorvastatin. The mechanism is boceprevir inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme responsible for the metabolic clearance of atorvastatin.",
      "management_text": "The benefits of using atorvastatin in combination with boceprevir should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. The product labeling for boceprevir recommends that atorvastatin dosage not exceed 40 mg daily during coadministration. Alternatively, other HMG-CoA reductase inhibitors that are not metabolized by CYP450 3A4 may be considered, such as fluvastatin, pravastatin, pitavastatin, and rosuvastatin. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23199,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Major",
      "effect": "Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.",
      "management_text": "The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of the HMG-CoA reductase inhibitor should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with clarithromycin. Fluvastatin, pitavastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23201,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Colchicine",
      "severity": "Major",
      "effect": "Coadministration of colchicine and HMG-CoA reductase inhibitors may increase the risk of myopathy due to a combination of pharmacodynamic and pharmacokinetic effects. These agents are individually myotoxic and may have additive or synergistic effects when used together. In addition, colchicine and some HMG-CoA reductase inhibitors are substrates of the CYP450 3A4 isoenzyme and P-glycoprotein efflux transporter, thus competitive inhibition may occur resulting in increased drug absorption and decreased excretion.",
      "management_text": "Extreme caution is advised if colchicine is used in combination with HMG-CoA reductase inhibitors, particularly in the elderly and patients with underlying renal or hepatic impairment. Some experts recommend checking the creatine kinase level a week or two after coadministration of these agents and after any dose increase, although such monitoring does not reliably prevent the occurrence of severe myopathy. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paraesthesia, and numbness. The drugs should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23203,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Danazol",
      "severity": "Major",
      "effect": "The use of danazol with higher dosages of certain HMG-CoA reductase inhibitors may be associated with an increased risk of myopathy. The proposed mechanism is danazol inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme responsible for the metabolic clearance of HMG-CoA reductase inhibitors like atorvastatin, lovastatin, simvastatin, as well as some of their pharmacologically active metabolites. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The benefits of the use of atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) in patients receiving danazol should be carefully weighed against the potential risks. If the combination is prescribed, lower dosages of the HMG-CoA reductase inhibitor should be considered. Fluvastatin, pravastatin, and rosuvastatin are probably safer alternatives in patients receiving danazol, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23206,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Major",
      "effect": "Coadministration with darunavir/ritonavir may significantly increase the plasma concentrations of atorvastatin. The mechanism is inhibition of the CYP450 3A4-mediated metabolism of atorvastatin by darunavir/ritonavir. High levels of statin or HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "Atorvastatin should be initiated at the lowest possible dosage when prescribed with darunavir/ritonavir. The dosage may be increased gradually based on clinical response and tolerance, but should not exceed 20 mg/day. Fluvastatin and rosuvastatin may be safer alternatives in patients treated with protease inhibitors, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23207,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fenofibric acid",
      "severity": "Major",
      "effect": "Data from observational studies suggest that the risk of severe myopathy and rhabdomyolysis is increased when fibric acid derivatives are coadministered with an HMG-CoA reductase inhibitor (i.e., statin), even in the absence of a marked pharmacokinetic interaction. Additive pharmacodynamic effects may be involved, since these agents individually have been associated with the development of myopathy. Although gemfibrozil has been implicated most often, presumably due to a pharmacokinetic interaction with statins that significantly increases their concentrations in plasma, other fibrates have also been involved.",
      "management_text": "Caution is advised if delayed-release fenofibric acid is coadministered with a statin. A lower dosage of the statin may be appropriate, particularly if the patient is already receiving the maximum dosage. Coadministration with the maximum dosage of a statin has not been evaluated in clinical studies and should be avoided unless the benefits are expected to outweigh the risks. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23212,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Pexidartinib",
      "severity": "Major",
      "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.",
      "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23227,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Major",
      "effect": "Coadministration with posaconazole may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 such as atorvastatin, cerivastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin). The mechanism is decreased clearance due to inhibition of CYP450 3A4 by posaconazole. The interaction has been studied with simvastatin. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The use of posaconazole in combination with HMG-CoA reductase inhibitors that are primarily metabolized by CYP450 3A4 is considered contraindicated. Fluvastatin, pitavastatin, pravastatin, and rosuvastatin may be suitable alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23228,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.",
      "management_text": "The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23231,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Simeprevir",
      "severity": "Major",
      "effect": "Coadministration with simeprevir may significantly increase the plasma concentrations of atorvastatin and its active metabolite, 2-hydroxyatorvastatin. The proposed mechanism is simeprevir inhibition of atorvastatin hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1) and intestinal metabolism via CYP450 3A4.",
      "management_text": "Atorvastatin therapy should be initiated at the lowest dosage necessary, but not exceed a dosage of 40 mg daily, when prescribed with simeprevir. Alternatively, fluvastatin may be substituted, as it has been shown to have no significant interaction with simeprevir. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23232,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Telaprevir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 including telaprevir may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors and their pharmacologically active metabolites that are primarily metabolized by the isoenzyme.",
      "management_text": "Due to the potential for severe interaction, concomitant use of atorvastatin, lovastatin, or simvastatin with telaprevir is considered contraindicated. Red yeast rice, which contains lovastatin, should also be avoided during treatment with telaprevir. Fluvastatin, pravastatin, and pitavastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23234,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Major",
      "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23236,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Troleandomycin",
      "severity": "Major",
      "effect": "Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.",
      "management_text": "The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of the HMG-CoA reductase inhibitor should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with clarithromycin. Fluvastatin, pitavastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23238,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "Coadministration with itraconazole may significantly increase the plasma concentrations of atorvastatin and potentiate the risk of statin-induced myopathy. The proposed mechanism is itraconazole inhibition of atorvastatin metabolism via intestinal and hepatic CYP450 3A4.",
      "management_text": "The benefits of using atorvastatin in combination with itraconazole should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. The lowest effective dosage of atorvastatin should be used, and should not exceed 20 mg/day when prescribed with itraconazole. Fluvastatin, pitavastatin, pravastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 35829,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Grazoprevir",
      "severity": "Major",
      "effect": "Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter. Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.",
      "management_text": "Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir. Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir. The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins. In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 96594,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Glecaprevir",
      "severity": "Major",
      "effect": "Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of atorvastatin, simvastatin, and their active acid metabolites. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of the statins and their metabolites by glecaprevir and pibrentasvir. Inhibition of CYP450 3A4-mediated metabolism may also contribute, as glecaprevir and pibrentasvir are weak inhibitors of the isoenzyme.",
      "management_text": "Concomitant use of atorvastatin or simvastatin with glecaprevir-pibrentasvir is not recommended. Other statins may be used with glecaprevir-pibrentasvir, but a dosage reduction may be required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185659,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Paritaprevir",
      "severity": "Major",
      "effect": "Theoretically, coadministration with ombitasvir/paritaprevir/ritonavir with or without dasabuvir may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors.  The proposed mechanism may involve inhibition of the hepatic uptake transporter OATP1B1 by paritaprevir and/or inhibition of CYP450 3A4 by ritonavir.",
      "management_text": "Concomitant use of atorvastatin and ombitasvir/paritaprevir/ritonavir with or without dasabuvir should be avoided.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 297766,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.",
      "management_text": "The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23197,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Clofibrate",
      "severity": "Major",
      "effect": "Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity.",
      "management_text": "Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23202,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Major",
      "effect": "Coadministration with conivaptan may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors and/or their pharmacologically active metabolites. The mechanism is conivaptan inhibition of CYP450 3A4 metabolism.",
      "management_text": "In general, lovastatin, red yeast rice (which contains lovastatin), and simvastatin should be avoided in patients treated with conivaptan due to the potential for severe interaction. Atorvastatin may possibly be used with caution, although clinical data are lacking. Patients currently receiving these agents should consider an interruption during administration of conivaptan, and allow an appropriate amount of time (at least one week) following completion of conivaptan therapy before resuming these medications. Conivaptan is not expected to interact with fluvastatin, pravastatin, and rosuvastatin, since these agents are not significantly metabolized by CYP450 3A4.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23204,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Major",
      "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their pharmacologically active metabolites. The proposed mechanism is cyclosporine inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme responsible for the metabolic clearance of HMG-CoA reductase inhibitors like atorvastatin, lovastatin, simvastatin. In addition, atorvastatin, its metabolites, and the active beta-hydroxyacid form of simvastatin, simvastatin acid, are substrates of the hepatic uptake transporter, organic anion transporting polypeptide (OATP) 1B1, which is also inhibited by cyclosporine. Use of cyclosporine with atorvastatin or other HMG-CoA reductase inhibitors has resulted in musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The concomitant use of atorvastatin in combination with cyclosporine should generally be avoided. Fluvastatin or pravastatin may be considered as alternatives in patients receiving cyclosporine as they are not extensively metabolized by CYP450 3A4. However, the benefits of the use of these medicines in combination with cyclosporine should be carefully weighed against the potential risks and dosages titrated with caution. The product labeling for fluvastatin recommends that, when used in combination with cyclosporine, the fluvastatin dose should not exceed 20 mg twice a day when given with cyclosporine. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23205,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Major",
      "effect": "Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.",
      "management_text": "The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of the HMG-CoA reductase inhibitor should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with clarithromycin. Fluvastatin, pitavastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23210,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Major",
      "effect": "Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity.",
      "management_text": "Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23211,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. If coadministration is required, a lower initial and maintenance dosage of the statin should be considered. Close monitoring for musculoskeletal toxicity is recommended, particularly during the initial months of therapy and following a dosage increase of either drug. Pitavastatin, pravastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. Fluvastatin may also be used with azole antifungal agents except fluconazole and voriconazole, both of which can inhibit fluvastatin metabolism via CYP450 2C9. Alternatively, an interruption of the statin may be considered during treatment with an azole antifungal agent. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23213,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.",
      "management_text": "The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23215,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Major",
      "effect": "Coadministration with ranolazine may increase the plasma concentrations of atorvastatin and potentiate the risk of statin-induced myopathy. The mechanism involves reduced clearance of atorvastatin due to inhibition of intestinal and hepatic CYP450 3A4 by ranolazine.",
      "management_text": "The benefits of using atorvastatin in combination with ranolazine should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered and close clinical monitoring advised if concomitant use is required. Fluvastatin, pitavastatin, pravastatin, and rosuvastatin may be safer alternatives in patients receiving ranolazine, since they are not substrates of CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23229,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.",
      "management_text": "The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23230,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Major",
      "effect": "Coadministration with telithromycin may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 such as atorvastatin, cerivastatin, lovastatin, and simvastatin. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telithromycin. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The use of telithromycin should be avoided in patients treated with atorvastatin, lovastatin, red yeast rice (which contains lovastatin), and simvastatin due to the potential for severe interaction. If telithromycin is prescribed in such patients, HMG-CoA reductase inhibitor therapy should be suspended until after completion of telithromycin treatment. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with telithromycin, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark-colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23235,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Major",
      "effect": "Protease inhibitors (PIs) may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism. High levels of HMG-CoA reductase inhibitory activity in plasma are associated with an increased risk of musculoskeletal toxicity, including myopathy and rhabdomyolysis, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The use of atorvastatin in combination with tipranavir-ritonavir should generally be avoided. Fluvastatin and pravastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23237,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.",
      "management_text": "The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. If coadministration is required, a lower initial and maintenance dosage of the statin should be considered. Close monitoring for musculoskeletal toxicity is recommended, particularly during the initial months of therapy and following a dosage increase of either drug. Pitavastatin, pravastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. Fluvastatin may also be used with azole antifungal agents except fluconazole and voriconazole, both of which can inhibit fluvastatin metabolism via CYP450 2C9. Alternatively, an interruption of the statin may be considered during treatment with an azole antifungal agent. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23240,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Major",
      "effect": "INTERVAL: Chronic administration of rifampin may increase or decrease the plasma concentrations of atorvastatin and atorvastatin acid depending on timing of administration.",
      "management_text": "To minimize impact of the interaction, manufacturers recommend that atorvastatin and rifampin doses be administered simultaneously. Monitoring for adequate hypolipidemic effect is advisable.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 35898,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Abametapir (topical)",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations. The proposed mechanism is high and prolonged systemic exposure to the metabolite abametapir carboxyl, which has been shown to be an in vitro inhibitor of CYP450 3A4, CYP450 2B6, and CYP450 1A2.",
      "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion. If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 519,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1782,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Trastuzumab emtansine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 9744,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.",
      "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14872,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of atorvastatin should be considered during coadministration with CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. Otherwise, pharmacologic response to atorvastatin should be closely monitored, and the dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15117,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.",
      "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15269,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Moderate",
      "effect": "Coadministration with fostemsavir may increase the plasma concentrations of most HMG-CoA reductase inhibitors (i.e., statins) to varying degrees. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1/1B3-mediated hepatic uptake by temsavir, the active moiety of fostemsavir. Inhibition of breast cancer resistance protein (BCRP)-mediated intestinal and hepatic transport of statins may also contribute.",
      "management_text": "The lowest effective dosage of a statin should be used when prescribed with fostemsavir, and the dosage titrated cautiously based on clinical response and adverse events. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever, malaise, and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15375,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Aliskiren",
      "severity": "Moderate",
      "effect": "Coadministration with atorvastatin may increase the plasma concentrations of aliskiren. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of aliskiren.",
      "management_text": "Caution is advised during coadministration of aliskiren with atorvastatin. Antihypertensive response should be monitored more closely following initiation, discontinuation, or change of dosage of atorvastatin in patients who are stabilized on their aliskiren regimen. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16758,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Moderate",
      "effect": "Coadministration with alpelisib may theoretically increase the plasma concentrations of drugs that are substrates of organic anion transporter (OAT3), intestinal breast cancer resistance protein (BCRP), and/or P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by alpelisib and/or its metabolite (BZG791).",
      "management_text": "Caution is advised if alpelisib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever alpelisib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18781,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.",
      "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21348,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23214,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of atorvastatin should be considered during coadministration with CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. Otherwise, pharmacologic response to atorvastatin should be closely monitored, and the dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23839,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Aurothioglucose",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35716,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Moderate",
      "effect": "Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35718,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Bempedoic acid",
      "severity": "Moderate",
      "effect": "Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, is decreased clearance due to bempedoic acid-mediated inhibition of OATP1B1 and 1B3.",
      "management_text": "Caution is advised if bempedoic acid is used concomitantly with drugs that are substrates of OATP1B1 or 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever bempedoic acid is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35719,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Benznidazole",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35720,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.",
      "management_text": "Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35722,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib. The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.",
      "management_text": "Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors. Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35723,
      "ingredient1": "Atorvastatin"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Moderate",
      "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.",
      "management_text": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35726,
      "ingredient1": "Atorvastatin"
    }
  ]
}